• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
Amgen
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Medical Professionals
  • Products
  • Update to U.S. Prescribing Information for Aranesp® and EPOGEN®

  • Overview
  • Products
  • Update to U.S. Prescribing Information for Aranesp® and EPOGEN®
  • Counterfeit Drug Statement
  • Information on Aranesp® Phase 3 Study in Cancer Patients
  • PRCA Update
  • Disease / Condition Info
  • Clinical Trials
  • Resources
  • R&D Vision
  • Reimbursement Connection®
  • Medical Information
  • Pharmacy Affairs
Update to U.S. Prescribing Information for Aranesp® and EPOGEN®

Amgen is committed to the highest standards of patient safety. The well-being of patients is Amgen’s highest priority.

  • Amgen Announces Update to U.S. Prescribing Information for Aranesp® and EPOGEN®
  • Letter to Healthcare Professionals
  • UPDATED: Prescribing information for Aranesp® (darbepoetin alfa)
  • UPDATED: Prescribing information for EPOGEN® (Epoetin alfa)

 


footer